ida care App: How Does Digital Support for Cancer Work?
Laura Chrobok 28.08.2026
Weeks can pass between two medical appointments. Pain, severe exhaustion or other symptoms, however, do not follow the appointment calendar. This is exactly where ida care comes in: patients with metastatic breast cancer regularly report digitally on how they are feeling. If their condition deteriorates noticeably, the treatment team can be informed.
Read more here about what lies behind the app, how digital symptom monitoring works and what the large German PRO-B study found. Above all, however, the question is: Where can an app like this provide meaningful support in cancer treatment — and where are its limits?
The ida care App as a Gap-Filler Between Two Appointments …
ida care is an application for digital symptom monitoring in metastatic breast cancer.
The app does not diagnose cancer, does not independently detect a growing tumour and does not make treatment decisions either. Its principle is much simpler: patients regularly report their symptoms, physical functioning and quality of life themselves.
Such information is referred to as Patient-Reported Outcomes, or PROs for short. Unlike laboratory values or the results of imaging examinations, this information comes directly from the patients themselves.
The underlying concept was investigated in the German PRO-B study. Patients in the intervention group completed digital questionnaires once a week. If certain values deteriorated, the system automatically generated an alert for the treating breast centres. The medical teams were then expected to contact the patients and, if necessary, initiate further measures (Gebert et al., 2024).
Put simply: patients report symptoms → the system detects notable changes → treatment teams are informed → medical staff decide what to do next.
The app is intended to ensure that changes observed between two medical appointments are brought to the attention of treatment teams more quickly.
Of course, patients can contact the clinic themselves, but understandably not every change is immediately recognised as important or reported. Some symptoms develop gradually, while others are initially given little attention.
At the next regular appointment, patients may then report retrospectively and sometimes incompletely — digital monitoring is intended to reduce such potential gaps in information. Symptoms are documented regularly, and notable changes can become visible earlier.
The Study …
PRO B was a randomised controlled multicentre study involving patients with metastatic breast cancer.
The intervention phase of the PRO-B study ran from May 2021 to March 2024. Between May 2021 and June 2023, a total of 924 patients from 52 certified German study centres were enrolled and randomly assigned to either the intervention or control group. A total of 909 patients were included in the primary analysis. The primary comparison between the two groups was conducted after six months. In addition, results after twelve months, among others, were evaluated.
The intervention group received a digital questionnaire every week. If certain values deteriorated, alerts were automatically sent to the treating centres. The respective medical teams were then expected to contact the patients within 48 hours.
The control group completed corresponding questionnaires only every three months and was not connected to this automatic alert system.
(Gebert et al., 2024; Karsten et al., 2025; Breidenbach et al., 2026)
The Results …
One important aspect was fatigue after six months of the study. Fatigue is far more than ordinary tiredness. The pronounced physical and mental exhaustion can be extremely burdensome and severely impair everyday life and quality of life. After six months, however, a clear difference emerged.
The average fatigue score was 54.5 points in the intervention group and 59.9 points in the control group. Since a higher score indicates more severe fatigue, the group with weekly monitoring performed better. Better scores were also observed in the intervention group for physical functioning and overall quality of life (Karsten et al., 2025).
Another study result is particularly striking: After twelve months, 88% of the patients in the intervention group were alive, compared with 85% in the control group. The statistical analysis of overall survival also showed an advantage in favour of alert-based monitoring (Karsten et al., 2025).
This is remarkable, but it is nevertheless important to interpret the findings correctly: The study shows that the alert-based care concept was associated with better overall survival.
The mechanisms underlying the observed differences have not been conclusively established by these results. However, digital monitoring facilitates the documentation and evaluation of collected data, allowing patients’ experiences in everyday life to be taken into greater account.
The Limitations ...
Collecting more data does not automatically mean better medicine. A digital application can, for example, detect that a patient is reporting significantly more severe pain or exhaustion.
Of course, the app does not know why. A deterioration may be due to the cancer itself, side effects of treatment, an infection, sleep problems, psychological distress or numerous other causes. Medical assessment therefore remains the responsibility of doctors and other healthcare professionals. And an alert is only helpful if someone actually responds to it.
The Outlook …
The PRO-B study has been completed, but ida care has not yet become part of routine, nationwide care. In June 2026, the G-BA recommended transferring the care concept into standard care. Health insurers involved in the project are planning to make routine use possible from as early as autumn 2026. In the long term, the new form of care is intended to be available to all people with statutory health insurance who have the corresponding diagnosis (Innovation Committee at the Federal Joint Committee, 2026; Charité, 2026).
Alert-based PRO monitoring must be taken seriously as a care concept. The question of how it should be further integrated into medical care must now finally be addressed at the health-policy level.
If digital monitoring helps ensure that patients receive medical assistance more quickly, the technology can genuinely add value – not as a replacement for doctors, but as an additional connection to them.
FAQ — (Further) Frequently Asked Questions About the ida care App
1. Who is the ida care app intended for?
The concept investigated in PRO B was aimed at patients with metastatic breast cancer. An equivalent benefit for other types of cancer cannot be inferred from this study.
2. Does ida care have to be used permanently?
In the PRO-B concept, symptoms were recorded digitally once a week. It is therefore not a form of permanent monitoring.
3. Will the costs of using the app be covered by statutory health insurance in the future?
That is the stated aim of transferring the concept into standard care, but it has not yet been implemented nationwide. In the long term, the care concept is intended to be made available to people with statutory health insurance who have the corresponding diagnosis.
Further information — also on many other topics — can be found on our blog. You can also find our “Medizinskandale” book series and the “Codex Humanus” (the fifth volume was recently published) in our online shop. We look forward to your visit.
Sources:
· Gebert, P. et al. (2024): “Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer,” Trials.
· Karsten, M. M. et al. (2026): “Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial,” JAMA Oncology.
· Breidenbach, C. et al. (2026): “Providers’ perspectives on implementing alert-based patient-reported outcome monitoring for stage IV breast cancer,” Journal of Patient-Reported Outcomes.
· Innovation Committee at the Federal Joint Committee (2026): “PRO B – PROM bei Brusterkrankungen – neue Wege in der Versorgung bei metastasiertem Brustkrebs,” G-BA Innovation Fund (Innovationsausschuss beim Gemeinsamen Bundesausschuss).
· Charité – Universitätsmedizin Berlin (2026): “Enge digitale Begleitung hilft Frauen mit Brustkrebs,” Charité.
Header images are AI-generated illustrative images.